Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

228.83
+1.330.58%
Volume:640.13K
Turnover:146.32M
Market Cap:14.12B
PE:-51.80
High:232.36
Open:227.18
Low:225.86
Close:227.50
52wk High:248.60
52wk Low:124.06
Shares:61.70M
Float Shares:60.08M
Volume Ratio:1.27
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4176
EPS(LYR):-4.4176
ROE:-818.43%
ROA:-6.86%
PB:-75.31
PE(LYR):-51.80

Loading ...

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga
·
Nov 12, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

Biotech stocks are coming back. Here's what's driving the sector higher.

Dow Jones
·
Nov 09, 2025

Ascendis Pharma announces new pooled analysis on TransCon PTH

TIPRANKS
·
Nov 07, 2025

Ascendis Pharma Reports TransCon PTH Sustains Renal Function Improvements in Hypoparathyroidism Over Three Years

Reuters
·
Nov 07, 2025

Teijin Pharma Wins Japan Approval for YORVIPATH Hypoparathyroidism Treatment

Reuters
·
Nov 06, 2025

Assessing Ascendis Pharma After Pipeline Updates and a 59.8% One-Year Surge

Simply Wall St.
·
Nov 05, 2025

Biotech Stocks Are Coming Back. Here's What's Driving The Sector Higher.

Dow Jones
·
Nov 04, 2025

Ascendis Pharma Reports 3-Year Renal Benefits of TransCon PTH in Hypoparathyroidism

Reuters
·
Nov 04, 2025

European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading

MT Newswires Live
·
Nov 04, 2025

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Dow Jones
·
Nov 03, 2025

Did a Fatal Adverse Event Just Shift Ascendis Pharma's (ASND) Yorvipath Investment Narrative?

Simply Wall St.
·
Oct 26, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT Newswires Live
·
Oct 21, 2025

RBC Capital remains buyer of Ascendis, says patient death unlikely drug related

TIPRANKS
·
Oct 21, 2025

Ascendis Pharma weakness follows death reported in FAERS, says BofA

TIPRANKS
·
Oct 21, 2025

How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story

Simply Wall St.
·
Oct 19, 2025

Ascendis Pharma Initiated at Strong Buy by Raymond James

Dow Jones
·
Oct 17, 2025

Ascendis Pharma a/S : Raymond James Initiates Coverage With Strong Buy Rating; Target Price $271

THOMSON REUTERS
·
Oct 17, 2025

Raymond James Initiates Ascendis Pharma A/S at Strong Buy

MT Newswires Live
·
Oct 17, 2025

Ascendis Pharma initiated with a Strong Buy at Raymond James

TIPRANKS
·
Oct 17, 2025